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Background: Current guidelines recommend genetic counselling and testing in patients with familial 
non-ischemic idiopathic cardiomyopathies with hypertrophic, dilated, restrictive or arrhythmogenic 
phenotype.1,2 We aimed to investigate genotype features of patients with non-ischemic cardiomyopa-
thies in advanced stage of heart failure in University Hospital Centre Zagreb. 
Methods: Genetic testing (single variant and multiple variant testing) was performed in part using the 
in-house genetics laboratory, and also in a collaborating genetics laboratory in Helsinki, Finland (Blue-
print Genetics). Pathogenic and likely pathogenic variants 
that established a molecular diagnosis were confirmed by 
Sanger sequencing. 
Results: From September 2016 to December 2020, we have 
performed genetic testing in 66 patients. Of this number, 
14 patients (8 males, 41.5±14.3 years) had advanced heart 
failure as evidenced by either having undergone heart 
transplantation, mechanical circulatory support implan-
tation, or were currently listed for heart transplantation. 
Before genetic testing, clinically observed phenotypes 
indicated dilated cardiomyopathy in 6 patients, restric-
tive cardiomyopathy in 6 patients, and arrhythmogenic 
cardiomyopathy in 2 patients. Diagnostic yield of the per-
formed genetic tests was relatively high, only one test did 
not identify any mutations, and 4/14 identified mutations 
that can currently be classified only as variants of uncer-
tain significance. Pathogenic and likely pathogenic muta-
tions predominantly affected genes coding proteins of the 
sarcomere, cellular and nuclear membrane, or pathologic 
protein such as transthyretin (Table 1). Genetic testing 
lead to change in the clinically determined diagnosis in 
4/14 patients. Results of genetic testing in this group of 
patients warranted further family clinical screening in all 
of the patients, and family genetic screening in 5 eligible 
patients. 
Conclusion: Genetic testing in our advanced heart failure population yields important information on 
etiology of the diseases, and indicates further family screening. 
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TABLE 1. Genotypes associated with clinically observed phenotypes.
Clinical phenotype DCM (N=6) RCM (N=6) ACM (N=2)
Gender (males) 3/6 4/6 1/2
Age (years) 34.6±11.9 49.9±14.4 36.9±12.7
Genotype
- pathogenic 1/6 1/6 1/6
TNNT2 FLNC PKP2
- likely pathogenic 2/6 3/6 1/6
FLNC TTR LMNA
DSP MYH7
- VUS 3/6 1/6 0/6
DMD, DES, DYSF, SGCB KCNA5
MYH7, PRDM16
FLNC
- negative 0/6 1/6 0/6
DCM: dilated cardiomyopathy, RCM: restrictive cardiomyopathy, ACM: arrhythmogenic cardi-
omyopathy, TNNT2: cardiac troponin T, FLNC: filamin C, PKP2: plakophilin 2, TTR: transthyretin, 
LMNA: lamin A/C, DSP: desmoplakin, MYH7: myosin heavy chain 7, DMD: dystrophin, DES: 
desmin, DYSF: dysferlin, SGCB: sarcoglycan beta, KCNA5: potassium voltage-gated channel 
subfamily A member 5, PRDM16: PR/SET Domain 16, VUS: variant of uncertain significance.
